Latest news with #JasonBrown
Yahoo
5 days ago
- Business
- Yahoo
QurAlis Announces New Global Headquarters
30,000 square foot state-of-the-art office suite, lab, and research facility doubles QurAlis' footprint in Cambridge's vibrant Alewife Biotech Park CAMBRIDGE, Mass., June 18, 2025--(BUSINESS WIRE)--QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company's new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive ("35 CPD"), doubles QurAlis' footprint in the heart of Cambridge's vibrant Alewife Biotech Park. "Maintaining our corporate headquarters in Cambridge positions us at the heart of a thriving biotechnology hub with world-class talent and leading research institutions," said Jason Brown, MBA, chief financial officer at QurAlis. "The facility at Alewife allowed us to expand our R&D footprint, lab capacity, and office space to support QurAlis' growth and enhance our leading precision medicine portfolio and platform capabilities. Our new headquarters provides our employees with a high-tech work environment conducive to collaboration and innovation with improved space and amenities. The space will continue to foster our mission-driven culture committed to discovering and developing medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases." QurAlis and its landlord, Healthpeak, fully built out and furnished QurAlis' lab and office suite prior to occupancy. QurAlis' new headquarters offers a larger space with enhanced lab and discovery resources and a 5,000 square foot conferencing space for meeting and collaboration. More than one-third of the new facility is dedicated to a state-of-the-art 11,000 square foot lab with an expansive tissue culture suite and addition of an onsite antisense oligonucleotide (ASO) chemistry manufacturing lab to support programs utilizing QurAlis' FlexASO® technology platform. FlexASO® was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases. "Healthpeak welcomes QurAlis to 35 Cambridgepark Drive," said Scott Bohn, chief development officer and head of lab at Healthpeak. "QurAlis' need for Class A lab space to progress their groundbreaking neuroscience work aligned seamlessly with our purpose-built life science campus, offering state-of-the-art amenities, a sustainable LEED Gold design, and unbeatable proximity to Alewife Station – an ideal environment for QurAlis' continued innovation and growth." Part of a 450,000 square foot RSF, three-building campus, 35 CPD is a LEED Gold 224,000 square foot RSF purpose-built life science building strategically located in West Cambridge directly across from the Alewife MBTA Station (Red line), at the end of Massachusetts Route 2, on Minuteman bike path and walkable to the Fresh Pond Reservation. 35 CPD, with attached garage, provides ample tenant amenities in the building including a Craft Food Hall, exclusive fitness center, private shower and locker rooms, secure bike room, client lounge, and activated outdoor spaces. QurAlis was represented in their search and lease negotiations by Carolyn Wheatley and Marc Consalvi at JLL. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn. View source version on Contacts Kathy 310-403-8951
Business Wire
5 days ago
- Business
- Business Wire
QurAlis Announces New Global Headquarters
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company's new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive ('35 CPD'), doubles QurAlis' footprint in the heart of Cambridge's vibrant Alewife Biotech Park. 'Maintaining our corporate headquarters in Cambridge positions us at the heart of a thriving biotechnology hub with world-class talent and leading research institutions,' said Jason Brown, MBA, chief financial officer at QurAlis. 'The facility at Alewife allowed us to expand our R&D footprint, lab capacity, and office space to support QurAlis' growth and enhance our leading precision medicine portfolio and platform capabilities. Our new headquarters provides our employees with a high-tech work environment conducive to collaboration and innovation with improved space and amenities. The space will continue to foster our mission-driven culture committed to discovering and developing medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases.' QurAlis and its landlord, Healthpeak, fully built out and furnished QurAlis' lab and office suite prior to occupancy. QurAlis' new headquarters offers a larger space with enhanced lab and discovery resources and a 5,000 square foot conferencing space for meeting and collaboration. More than one-third of the new facility is dedicated to a state-of-the-art 11,000 square foot lab with an expansive tissue culture suite and addition of an onsite antisense oligonucleotide (ASO) chemistry manufacturing lab to support programs utilizing QurAlis' FlexASO® technology platform. FlexASO® was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases. 'Healthpeak welcomes QurAlis to 35 Cambridgepark Drive,' said Scott Bohn, chief development officer and head of lab at Healthpeak. 'QurAlis' need for Class A lab space to progress their groundbreaking neuroscience work aligned seamlessly with our purpose-built life science campus, offering state-of-the-art amenities, a sustainable LEED Gold design, and unbeatable proximity to Alewife Station – an ideal environment for QurAlis' continued innovation and growth.' Part of a 450,000 square foot RSF, three-building campus, 35 CPD is a LEED Gold 224,000 square foot RSF purpose-built life science building strategically located in West Cambridge directly across from the Alewife MBTA Station (Red line), at the end of Massachusetts Route 2, on Minuteman bike path and walkable to the Fresh Pond Reservation. 35 CPD, with attached garage, provides ample tenant amenities in the building including a Craft Food Hall, exclusive fitness center, private shower and locker rooms, secure bike room, client lounge, and activated outdoor spaces. QurAlis was represented in their search and lease negotiations by Carolyn Wheatley and Marc Consalvi at JLL. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn.
Yahoo
14-06-2025
- Business
- Yahoo
MRO acquires clinical data management platform Q-Centrix from TPG Growth
US-based clinical data exchange company MRO has acquired Q-Centrix, an enterprise clinical data management platform previously owned by TPG Growth. Q-Centrix is a comprehensive data management platform designed to reduce complexity, expedite decisions and advance clinical outcomes. MRO said the acquisition would enable hospitals and health systems to convert fragmented clinical data into actionable insights, expediting the exchange of clinical data across the sector. The deal is expected to create scalable value for healthcare providers, payers and life sciences, supporting more precise decision-making and broader clinical applications. MRO CEO Jason Brown said: 'At MRO, we believe there is tremendous untapped value in unlocking and leveraging clinical data that resides in fragmented, siloed systems today. 'Combining MRO's leading clinical data exchange solutions and Q-Centrix's clinical data management capabilities creates a category-defining, fit-for-purpose platform, enabling high fidelity, low latency acquisition, abstraction, curation and exchange of clinical data to power better patient care and reduce costs across the healthcare ecosystem.' The combined entity will provide services to more than 2,000 health systems and hospitals, as well as over 7,000 clinics and almost 250 payers. By enriching and curating clinical data, MRO and Q-Centrix aim to deliver scalable value, facilitating precise decision-making and wider clinical applications. Q-Centrix CEO Milton Silva-Craig said: 'MRO and Q-Centrix share a commitment to advancing the industry in service of our customers. 'That focus is fuelling the creation of a first-of-its-kind platform—seamlessly integrating systems and delivering structured, highly valuable data sets to support clinical care, operational performance, breakthrough research, and regulatory compliance. 'Purpose-built around our customers' most pressing needs, this is innovation where it matters most.' The acquisition is supported by healthcare technology investors such as private equity company Parthenon Capital, which has reaffirmed its support for MRO with a new investment. The parties have not disclosed the value of the deal. "MRO acquires clinical data management platform Q-Centrix from TPG Growth" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Malaysian Reserve
04-06-2025
- Business
- Malaysian Reserve
BPD Launches New Strategic Advisory and AI-Driven Services to Help Healthcare Leaders Stay Ahead of What's Next
Launch of additional AI services, expanded data offerings, and Policy ICU furthers BPD's goal of delivering the future to healthcare's leading brands BOCA RATON, Fla., June 3, 2025 /PRNewswire/ — BPD, the home for healthcare's leading brands, announced the expansion of its strategic services to meet growing demand from health systems navigating rapid industry shifts. The firm's latest offerings include AI advisory programs, precision marketing tools, enhanced data consulting services, and a new thought leadership platform offering that is focused on healthcare policy. This expansion builds on BPD's commitment to helping health systems move faster, act smarter, and lead more boldly through transformation. 'As the market leader in data solutions & analytics for leading healthcare systems for years, our clients want to be empowered with an enhanced toolset that allows them to drive higher ROI, move faster and work smarter,' said Anne DiNapoli Block, BPD's Managing Director of Data Solutions & Analytics. Precision Marketing & Data Solutions BPD has also expanded its data strategy and performance offerings, including: New Precision Marketing packages, from entry-level models to enterprise-level campaigns that drive up to 20x ROI; Segmentation Support to enable smarter audience targeting and message customization; A proprietary Market Assessment Tool to identify market opportunities; and Data Consulting Services that help clients activate and interpret the full potential of their data ecosystems. AI Consultation: Built for What's Next BPD's new AI Consultation Suite gives marketing and communications leaders the tools they need to assess, apply, and lead with AI—responsibly and effectively. The suite includes: Marketing AI Accelerator – Built specifically for health system marketing & communication teams, the Marketing AI Accelerator fast-tracks your AI expertise—equipping you to integrate AI into your workflows, champion organizational change, and position your team as an industry leader in an AI future. This offering includes two levels of engagement: Core Option: An AI program focused on education. Includes training team to understand AI and how to implement best practices within a health system marketing. After six months you are at an advanced stage and beginning the transformation of work. Pro Option: An immersive AI experience focused not just on education, but also immersing the team in actual work style and workflow changes relative to your specific environment. After six months, the team will be fully up-to-speed on AI and already implementing it. 'Today's healthcare leaders need to understand how to quickly and effectively deploy AI within their world,' said Jason Brown, CEO of BPD. 'To operate more efficiently. To practice their craft at the top of their license. To drive better business results.' Policy ICU: A Platform for Policy Intelligence Also launching is Policy ICU, BPD's new offering and thought leadership platform built for healthcare CMOs, CCOs, and public affairs executives. Designed to meet rising demand for strategic insight into federal policy developments, the Policy ICU offering provides monitoring, analysis and communications recommendations of federal policy changes customized to your organization. Additionally, BPD has launched a free online resource, the Policy ICU website, which includes: Real-time updates and weekly analysis on D.C.-driven changes that may impact healthcare organizations; Access to BPD's communications advisors for strategic interpretation and planning; and Peer networking and early access to content before the platform's public debut. 'Health systems have to stay ahead of the curve on understanding the ramifications of a rapidly shifting federal landscape,' said Ryan Colaianni, Chief Communications Officer at BPD. 'Policy ICU provides health system leaders with the insights to make more informed decisions during a time of unprecedented uncertainty.' About BPDBPD is a marketing services firm that delivers the future to healthcare's leading brands. We provide fully integrated solutions — branding, marketing, communications and business consulting — which are technology-enabled, AI-infused, and supported by our proprietary data platform. All to ignite greatness in our clients and bring better health to more people. Our clients range from the largest health systems to prestigious academic medical centers to leading healthcare innovators and care enablers. For more information visit Media Contact:Candy Boakyewaacboakyewaa@
Yahoo
03-06-2025
- Business
- Yahoo
BPD Launches New Strategic Advisory and AI-Driven Services to Help Healthcare Leaders Stay Ahead of What's Next
Launch of additional AI services, expanded data offerings, and Policy ICU furthers BPD's goal of delivering the future to healthcare's leading brands BOCA RATON, Fla., June 3, 2025 /PRNewswire/ -- BPD, the home for healthcare's leading brands, announced the expansion of its strategic services to meet growing demand from health systems navigating rapid industry shifts. The firm's latest offerings include AI advisory programs, precision marketing tools, enhanced data consulting services, and a new thought leadership platform offering that is focused on healthcare policy. This expansion builds on BPD's commitment to helping health systems move faster, act smarter, and lead more boldly through transformation. "As the market leader in data solutions & analytics for leading healthcare systems for years, our clients want to be empowered with an enhanced toolset that allows them to drive higher ROI, move faster and work smarter," said Anne DiNapoli Block, BPD's Managing Director of Data Solutions & Analytics. Precision Marketing & Data Solutions BPD has also expanded its data strategy and performance offerings, including: New Precision Marketing packages, from entry-level models to enterprise-level campaigns that drive up to 20x ROI; Segmentation Support to enable smarter audience targeting and message customization; A proprietary Market Assessment Tool to identify market opportunities; and Data Consulting Services that help clients activate and interpret the full potential of their data ecosystems. AI Consultation: Built for What's Next BPD's new AI Consultation Suite gives marketing and communications leaders the tools they need to assess, apply, and lead with AI—responsibly and effectively. The suite includes: Marketing AI Accelerator – Built specifically for health system marketing & communication teams, the Marketing AI Accelerator fast-tracks your AI expertise—equipping you to integrate AI into your workflows, champion organizational change, and position your team as an industry leader in an AI future. This offering includes two levels of engagement: Marketing Function Reimagining – A strategic redesign of the modern health system marketing team and operations. Custom AI Consulting – Tailored engagements built around each organization's needs, including innovation sprints, tech stack evaluation, and future-focused roadmap development. "Today's healthcare leaders need to understand how to quickly and effectively deploy AI within their world," said Jason Brown, CEO of BPD. "To operate more efficiently. To practice their craft at the top of their license. To drive better business results." Policy ICU: A Platform for Policy Intelligence Also launching is Policy ICU, BPD's new offering and thought leadership platform built for healthcare CMOs, CCOs, and public affairs executives. Designed to meet rising demand for strategic insight into federal policy developments, the Policy ICU offering provides monitoring, analysis and communications recommendations of federal policy changes customized to your organization. Additionally, BPD has launched a free online resource, the Policy ICU website, which includes: Real-time updates and weekly analysis on D.C.-driven changes that may impact healthcare organizations; Access to BPD's communications advisors for strategic interpretation and planning; and Peer networking and early access to content before the platform's public debut. "Health systems have to stay ahead of the curve on understanding the ramifications of a rapidly shifting federal landscape," said Ryan Colaianni, Chief Communications Officer at BPD. "Policy ICU provides health system leaders with the insights to make more informed decisions during a time of unprecedented uncertainty." About BPDBPD is a marketing services firm that delivers the future to healthcare's leading brands. We provide fully integrated solutions — branding, marketing, communications and business consulting — which are technology-enabled, AI-infused, and supported by our proprietary data platform. All to ignite greatness in our clients and bring better health to more people. Our clients range from the largest health systems to prestigious academic medical centers to leading healthcare innovators and care enablers. For more information visit Media Contact:Candy Boakyewaacboakyewaa@ View original content to download multimedia: SOURCE BPD Healthcare Sign in to access your portfolio
